Sodium-glucose cotransporter-2 inhibitors (SGLT2i) deliver proven cardio-renal benefits in chronic heart failure and chronic kidney disease (CKD); however, the safety profile of these agents when initiating administration during the index STEMI admission remains poorly characterized. The gene discussed is SLC5A2; the disease is congestive heart failure.